Humanetics to use federal grant to advance BIO 300 as IPF treatment
The pharmaceutical company Humanetics will use a federal grant to fund a series of studies aimed at advancing the development of BIO 300 for idiopathic pulmonary fibrosis (IPF) — for one, testing the treatment candidate for its effectiveness in easing lung scarring, or fibrosis. BIO 300 is thought to…